头颈鳞状细胞癌的免疫治疗

严晓菊; 徐开伦; 张欣欣

doi:10.13201/j.issn.1001-1781.2017.13.024

头颈鳞状细胞癌的免疫治疗

- 1. 川北医学院附属广元市中心医院耳鼻咽喉头颈外科(四川广元, 628000);
- 2. 解放军总医院耳鼻咽喉头颈外科

详细信息

通讯作者: 徐开伦,E-mail:gyxukailun@163.com; 张欣欣,E-mail:xinxinzhang66@hot.com

中图分类号: R739.6

收稿日期: 2016-12-31

Immunotherapies for head and neck squamous cell carcinoma

More Information

Corresponding authors: XU Kailun ; ZHANG Xinxin

Received Date: 31 December 2016

摘要

- 头颈鳞状细胞癌 /
- 免疫逃逸 /
- 细胞因子 /
- 免疫检查点抑制剂 /
- 肿瘤疫苗
Abstract: The Head and neck squamous cell carcinoma(HNSCC) is a group of heterogeneous diseases. Patients with HNSCC demonstrate poor prognosis and survival time with standard therapy, especially in patients with advanced HNSCC. Recurrence and metastasis have not yet been effectively controlled. The immune profile in HNSCC, whether caused by carcinogen exposure or human papillomavirus(HPV), showed significantly immunosuppression. With the understanding of the complex interaction between tumor and immune system and immune escape mechanism of HNSCC, new immunotherapies have been generating. This article will summarize the immunological mechanism and immune therapy of HNSCC currently.
- head and neck squamous cell carcinoma /
- immune escape /
- cell factor /
- immunotherapy cytokines /
- tumor vaccine

HTML全文

参考文献(44)

[1]	FERLAY J, SHIN H R, BRAY F, et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN2008[J].Int J Cancer, 2010, 127:2893-917.
[2]	JEMAL A, SIEGEL R, XU J, et al.Cancer statistics, 2010[J].CA Cancer J Clin, 2010, 60:277-300.
[3]	BAXI S, FURY M, GANLY I, et al.Ten years of progress in head and neck cancers[J].J Natl Compr Canc Netw, 2012, 10:806-810.
[4]	LALAMI Y, AWADA A.Innovative perspectives of immunotherapy in head and neck cancer.From relevant scientific rationale to effective clinical practice[J].Cancer Treat Rev, 2016, 43:113-123.
[5]	CAMPOLI M, CHANG C C, OLDFORD S A, et al.HLA antigen changes in malignant tumors of mammary epithelial origin:molecular mechanic and clinical implication[J].Breast Dis, 2004, 20:105-125.
[6]	JOYCE J A, FEARON D T.T cell exclusion, immune privilege, and the tumor microenvironment[J].Science, 2015, 348:74-80.
[7]	FERRIS R L.Immunology and Immunotherapy of Head and Neck Cancer[J].J Clin Oncol, 2015, 33:3293-3304.
[8]	OSTRAND-ROSENBERG S, SINHA P.Myeloidderived suppressor cells:Linking inflammation and cancer[J].J Immunol, 2009, 182:4499-4506.
[9]	ZHANG C, HU X, LIU X Y, et al.Effect of tumorassociated macrophages on gastric cancer stem cell in omental milky spots and lymph node micrometastasis[J].Int J Clin Exp Pathol, 2015, 8:13795-13805.
[10]	DE PALMA M, LEWIS C E.Macrophage regulation of tumor responses to anticancer ther apies[J].Cancer Cell, 2013, 23:277-286.
[11]	MEMPEL T R, PITTET M J, KHAZAIE K, et al.Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation[J].Immunity, 2006, 25:129-141.
[12]	KERKAR S P, RESTIFO N P.Cellular constituents of immune escape within the tumor miro-environment[J].Cancer Res, 2012, 72:3125-130.
[13]	REICHERT T E, STRAUSS L, WAGNER E M, et al.Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carino ma[J].Clin Cancer Res, 2002, 8:3137-3145.
[14]	HOFFMANN T K, DWORACKI G, TSUKIHIROT, et al.Spontaneous apoptosis of circulating Tlymph ocytes in patients with head and neck cancer and its clinical importance[J].Clin Cancer Res, 2002, 8:2553-2562.
[15]	VERMORKEN J B, MESIA R, RIVERA F, et al.Platinum-based chemotherapy plus cetuximab in head and neck cancer[J].N Engl J Med, 2008, 359:1116-1127.
[16]	PARDOLL D M.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer, 2012, 12:252-264.
[17]	ZANDBERG D P, STROME S E.The role of the PD-L1:PD-1pathway in squamous cell carcinoma of the head and neck[J].Oral Oncol, 2014, 50:627-632.
[18]	GAJEWSKI T F, SCHREIBER H.Innate and adaptive immune cells in thetumor miroenvironment[J].Nat Immunol, 2013, 14:1014-1022.
[19]	吴介恒, 杨安钢, 温伟红.PD-1/PD-L1参与肿瘤免疫逃逸的研究进展[J].细胞与分子免疫学杂志, 2014, 30(7):777-780.
[20]	DULOS J, CARVEN G J, VAN BOXTEL S J, et al.PD-1blockade augments Th1and Th17and suppresses Th2responses in peripheral blood from patients with prostate and advanced melanoma cancer[J].J Immunother, 2012, 35:169-178.
[21]	SCHLOM J.Therapeutic cancer vaccines:current status and moving forward[J].J Natl Cancer Inst, 2012, 104:599-613.
[22]	VENUTI A, CURZIO G, MARIANI L, et al.Immunotherapy of HPV-associated cancer:DNA/plantderived vaccines and new orthotopic mouse models[J].Cancer Immunol Immunother, 2015, 64:1329-1338.
[23]	HERRERO R, QUINT W, HILDESHEIM A, et al.Reduced prevalence of oral human papillomavirus (hpv) 4years after bivalent hpv vaccination in a randomized clinical trial in costa rica[J].PLoS One, 2013, 8:e68329-e68329.
[24]	SKEATE J G, WOODHAM A W, EINSTEIN M H, et al.Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases[J].Hum Vaccin Immunother, 2016,[Epub ahead of print].
[25]	SCHULER P J, HARASYMCZUK M, VISUS C, et al.PhaseⅠdendritic cell p53peptide vaccine for head and neck cancer[J].Clin Cancer Res 2014;20:2433-2444.
[26]	WHITESIDE T L, FERRIS R L, SZCZEPANSKI M, et al.Dendritic cell-based autologpus tumor vaccines for head and neck squamous cell carcinoma[J].Head Neck, 2016, 38:E494-501.
[27]	VOSKENS C J, SEWELL D, HERTZANO R, et al.Induction of MAGE-A3 and HPV-16immunity by Trojan vaccines in patients with head and neck carcinoma[J].Head Neck, 2012, 34:1734-1746.
[28]	RADVANYI L G, BERNATCHEZ C, ZHANG M, et al.Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients[J].Clin Cancer Res, 2012, 18:6758-6770.
[29]	TO W C, WOOD B G, KRAUSS J C, et al.Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck:aphase 1study[J].Arch Otolaryngol Head Neck Surg, 2000, 126:1225-1231.
[30]	CHIA W K, TEO M, WANG W W, et al.Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma[J].Mol Ther, 2014, 22:132-139.
[31]	JIANG P, ZHANG Y, WANG H, et al.Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC[J].Int Immunopharmacol, 2015, 28:208-214.
[32]	DE COSTA A M, YOUNG M R.Immunotherapy for head and neck cancer:advances and deficiencies[J].Anticancer Drugs, 2011, 22:674-681.
[33]	LOPEZ-ALBAITERO A, LEE S C, MORGAN S, et al.Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NKcell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells[J].Cancer Immunol Immunother, 2009, 58:1853-1864.
[34]	SRIVASTAVA R M, LEE S C, FILHO P A A, et al.cetuximab-activated natural kil-Ler (NK) and dendritic cells (DC) collaborate to trigger tumor antigen-specific T cell immunity in head and neck cancer patients[J].Clin Cancer Res, 2013, 19:1858-1872.
[35]	VERMORKEN J B, HERBST R S, LEON X, et al.Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinumbased therapies[J].Cancer, 2008, 112:2710-2719.
[36]	BONNER J A, HARARI P M, GIRALT J, et al.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck[J].N Engl J Med, 2006, 354:567-578.
[37]	ECONOMOPOULOU P, PERISANIDIS C, GIO-TAKIS E I, et al.The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC):anti-tumor immunity and clinical applications[J].Ann Transla Med, 2016, 4:173-176.
[38]	BRAHMER J R, TYKODI S S, CHOW L Q, et al.Safety and activity of anti-PD-L1antibody in patients with advanced cancer[J].N Engl J Med, 2012, 366:2455-2465.
[39]	LAURA Q M, HADDAD R, et al.Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN):Preliminary results from KEYNOTE-012expansion cohort[J].J Clin Oncol, 2016, 34:3838-3845.
[40]	RIBAS A.Tumour immunotherapy directed at PD 1[J].N Engl J Med, 2012, 366:2517-2519.
[41]	POSTOW M A.Nivolumab and ipilimumab versus ipilimumab in untreated melanoma[J].N Engl J Med, 2015, 372:2006-2017.
[42]	JIE H B.CTLA-4(+) regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis[J].Cancer Res, 2015, 75:2200-2210.
[43]	黄方, 郝思国.抗肿瘤疫苗的研究进展及应用现状[J].实用医学杂志, 2016, 32(18):2967-2970.
[44]	JIANG P, ZHANG Y, WANG H, et al.Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC[J].Int Immunopharmacol, 2015, 28:208-214.